SCHEMBL30258276

SCHEMBL30258276

CC(C)(C)OC(=O)N1CCC(c2ccc3c(c2)CCN3)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.51
MAPT P10636 3/20 0.50
MAPK1 P28482 2/20 0.50
KDM4E B2RXH2 1/20 0.50
THRB P10828 1/20 0.50
DDB1 Q16531 2/20 0.48
CRBN Q96SW2 2/20 0.48
PDE4B Q07343 1/20 0.47
HTT P42858 2/20 0.46
ALDH1A1 P00352 4/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX15 P16050 1/20 0.44
CYP2C19 P33261 1/20 0.44
GPR119 Q8TDV5 4/20 0.44
IGF1R P08069 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31442938 1.00 NAMPT (0.51) NAMPTMAPTMAPK1KDM4ETHRB
SCHEMBL16047746 0.81 CRBN (0.58) NAMPTMAPTKDM4ETHRBDDB1
SCHEMBL30847573 0.81 CRBN (0.58) NAMPTMAPTKDM4ETHRBDDB1
SCHEMBL30659344 0.81 KDM4E (0.49) NAMPTMAPTMAPK1KDM4ETHRB
SCHEMBL21800200 0.80 NAMPT (0.54) NAMPTMAPTKDM4ETHRBDDB1
SCHEMBL25221277 0.79 ALDH1A1 (0.52) NAMPTMAPTMAPK1DDB1CRBN
SCHEMBL29967522 0.79 NAMPT (0.55) NAMPTMAPTKDM4ETHRBDDB1
SCHEMBL23410956 0.79 NAMPT (0.55) NAMPTMAPTKDM4ETHRBDDB1
SCHEMBL30543348 0.79 GPR119 (0.62) NAMPTMAPTKDM4ETHRBDDB1
SCHEMBL19725554 0.79 GPR119 (0.40) MAPK1KDM4EDDB1CRBNALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-18 US disclosed
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-04 US disclosed
US-12421220-B2 Bicyclic-substituted glutarimide cereblon binders C4 THERAPEUTICS, INC. (US) 2025-09-23 US disclosed
US-20250122179-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-04-17 US disclosed
EP-4536656-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 Therapeutics, Inc. (US) 2025-04-16 EP disclosed
WO-2023239750-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
WO-2023059792-A1 CORONAVIRUS NON-STRUCTURAL PROTEIN 3 DEGRADING COMPOUNDS C4 THRAPEUTICS, INC. (US) 2023-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 NAMPT 4445/4885MAPT 1299/4885MAPK1 4388/4885
US-20250122179-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 NAMPT 4445/4885MAPT 1299/4885MAPK1 4388/4885
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 NAMPT 4445/4885MAPT 1299/4885MAPK1 4388/4885
US-12421220-B2 Bicyclic-substituted glutarimide cereblon binders CRBN, STUB1, CUL1 NAMPT 4445/4885MAPT 1299/4885MAPK1 4388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.